Therefore, PD-L1 regulates cancer cell metabolism through Chk-α, and targeting both PD-L1 and Chk-α in combination may be beneficial to enhance antitumor immune cell surveillance to improve response to immune checkpoint blockade therapy. This evidence concerns the gene CD274 and cancer.